HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

280.00p
   
  • Change Today:
    -7.00p
  • 52 Week High: 352.00
  • 52 Week Low: 173.60
  • Currency: UK Pounds
  • Shares Issued: 871.26m
  • Volume: 4,178
  • Market Cap: £2,439.54m
  • RiskGrade: 226

Latest ShareCast News

Hutchmed publishes positive sovleplenib trial results

By Josh White

Date: Monday 17 Jun 2024

(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Hutchmed China launches two cancer treatment trials

By Josh White

Date: Tuesday 14 May 2024

(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.

Hutchmed China to make several presentations at cancer research meeting

By Josh White

Date: Friday 05 Apr 2024

(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.

Hutchmed endometrial cancer treatment gets prior... 02-Apr-2024 ShareCast
Hutchmed cancer treatment indication accepted fo... 28-Mar-2024 ShareCast
Hutchmed partner Inmagene exercises options over... 02-Feb-2024 ShareCast
Hutchmed's 'Elunate' approved under new Hong Kon... 30-Jan-2024 ShareCast
Hutchmed application for thrombocytopenia treatm... 11-Jan-2024 ShareCast
Hutchmed completes trial enrolment, keeps drugs ... 13-Dec-2023 ShareCast
Hutchmed completes trial enrolment, keeps drugs ... 13-Dec-2023 ShareCast
Hutchmed confirms new drug application for fruqu... 29-Sep-2023 ShareCast
Director dealings: IPF non-exec picks up shares,... 14-Sep-2023 ShareCast
Hutchmed reports progress on two oncology fronts 12-Sep-2023 ShareCast
Hutchmed tumour therapy candidate gets breakthro... 29-Aug-2023 ShareCast
Hutchmed meets all endpoints in platelet disorde... 21-Aug-2023 ShareCast
Hutchmed launches new phase one study in China 10-Jul-2023 ShareCast
Hutchmed China's colorectal cancer study to be p... 16-Jun-2023 ShareCast
US FDA gives priority to Hutchmed's colorectal c... 26-May-2023 ShareCast
Hutchmed's gastric cancer treatment accepted for... 18-Apr-2023 ShareCast
Hutchmed completes rolling FDA submission for co... 31-Mar-2023 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 280.00p
Change Today -7.00p
% Change -2.44 %
52 Week High 352.00
52 Week Low 173.60
Volume 4,178
Shares Issued 871.26m
Market Cap £2,439.54m
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.97% below the market average72.97% below the market average72.97% below the market average72.97% below the market average72.97% below the market average
49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average49.02% below the sector average
Price Trend
48.90% above the market average48.90% above the market average48.90% above the market average48.90% above the market average48.90% above the market average
77.36% above the sector average77.36% above the sector average77.36% above the sector average77.36% above the sector average77.36% above the sector average
Income Not Available
Growth
67.19% above the market average67.19% above the market average67.19% above the market average67.19% above the market average67.19% above the market average
88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average88.57% above the sector average

HCM Dividends

No dividends found

Trades for 18-Jun-2024

Time Volume / Share Price
08:42 797 @ 280.00p
08:38 2,203 @ 281.00p
08:35 148 @ 281.00p
08:27 381 @ 282.80p
08:26 500 @ 281.00p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page